Factors associated with duloxetine treatment among patients with major depressive disorder in Veterans Health Administration: A retrospective study

Current Medical Research and Opinion

Volumn 26, Issue 12, 2010, Pages 2715-2721

  Shi, Lizheng ^a,b,c   Liu, Jinan ^a,c   Campbell, Claudia ^a   Zhao, Yang ^d  

^a TULANE UNIVERSITY   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

Antidepressant; Major depressive disorder; Retrospective study; Veterans

Indexed keywords

AMFEBUTAMONE; BUTORPHANOL; CODEINE; DEXTROPROPOXYPHENE; DULOXETINE; FENTANYL; HYDROCODONE; HYDROMORPHONE; LEVORPHANOL; METHADONE; MIRTAZAPINE; MORPHINE; OXYCODONE; PENTAZOCINE; PETHIDINE; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; AGED; ARTICLE; COMORBIDITY; DRUG USE; DYSLIPIDEMIA; EMERGENCY CARE; FEMALE; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONOTHERAPY; PAIN; PREDICTOR VARIABLE; RETROSPECTIVE STUDY; SUBSTANCE ABUSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SOCIOECONOMIC FACTORS; THIOPHENES; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VETERANS HEALTH; YOUNG ADULT;

EID: 78349241037     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.530140     Document Type: Article

References (29)

1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105
2. Birnbaum H, Greenberg PE, Tang J, et al. Antidepressant treatment patterns and costs among US employees. J Med Econ 2009;12:36-45
3. Murray CJL, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436-42
4. Brannan SK, Mallinckrodt CH, Brown EB, et al. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. [See comment.] J Psychiatr Res 2005;39:43-53
5. Stewart DE. Physical symptoms of depression: unmet needs in special populations. J Clin Psychiatry 2003;64(Suppl. 7):12-16
6. McIntyre RS, Konarski JZ. Duloxetine: pharmacoeconomic implications of an antidepressant that alleviates painful physical symptoms. Expert Opin Pharmacother 2005;6:707-13
7. Fishbain DA. The association of chronic pain and suicide. Semin Clin Neuropsychiatry 1999;4:221-7
8. Fava M, Wiltse C, Walker D, et al. Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorder. J Affect Disord 2009; 113:263-71
9. Arnold LM, Meyers AL, Sunderajan P, et al. The effect of pain on outcomes in a trial of duloxetine treatment of major depressive disorder. Ann Clin Psychiatry 2008;20:187-93
10. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder, 2nd Edn. 2005
11. Department of Veterans Affairs, Department of Defense. VA/DoD Clinical Practice Guideline for Management of Major Depressive Disorder (MDD). 2009.
12. Bair MJ, Robinson RL, Eckert GJ, et al. Impact of pain on depression treatment response in primary care. Psychosom Med 2004;66:17-22
13. Brecht S, Courtecuisse C, Debieuvre C, et al. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial. [See comment.] J Clin Psychiatry 2007;68:1707-16
14. Schatzberg AF. Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder. J Clin Psychiatry 2003;64(Suppl. 13):30-7
15. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004;24:389-99
16. Vis P, van Baardewijk M, Einarson T. Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials. Ann Pharmacother 2005;39:1798-807
17. Goldstein DJ, Lu Y, Detke MJ, et al. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics 2004;45:17-28
18. Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007;164: 900-9
19. Howland RH, Wilson MG, Kornstein SG, et al. Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression. Ann Clin Psychiatry 2008;20:209-18
20. Perahia DGS, Quail D, Desaiah D, et al. Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression. J Psychiatr Res 2009;43:512-18
21. Rubin RR, Ma Y, Peyrot M, et al. Antidepressant medicine use and risk of developing diabetes during the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care 2010 [Epub ahead of print]
22. Shi L, Thiebaud P, McCombs JS. The impact of unrecognized bipolar disorders for patients treated for depression with antidepressants in the fee-for-services California Medicaid (Medi-Cal) program. J Affect Disord 2004;82:373-83
23. U.S. Department of Health and Human Services. ICD-9-CM Official Guidelines for Coding and Reporting. 2008 [cited 2010 Oct 19]; Available from: http://www.flashcode.com/help-resources/icdguide.pdf
24. O'Connor PJ, Rush WA, Pronk NP, et al. Identifying diabetes mellitus or heart disease among health maintenance organization members: sensitivity, specificity, predictive value, and cost of survey and database methods. Am J Manag Care 1998;4:335-42
25. Palos GR, Mendoza TR, Mobley GM, et al. Asking the community about cutpoints used to describe mild, moderate, and severe pain. J Pain 2006;7:49-56
26. Sullivan MD, Edlund MJ, Fan MY, et al. Trends in use of opioids for non-cancer pain conditions 2000-2005 in commercial and Medicaid insurance plans: the TROUP study. Pain 2008;138:440-9
27. Maloney P, McIntosh EG. Chronic low back pain and depression in a sample of veterans. Percept Mot Skills 2001;92:348
28. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001;25:871-80
29. Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clin Proc 2009;84:593-601